Wird geladen...
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
IMPORTANCE: Immunomodulatory anticancer drugs, such as the anti–programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation wit...
Gespeichert in:
| Veröffentlicht in: | JAMA Dermatol |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5061067/ https://ncbi.nlm.nih.gov/pubmed/26222619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2015.1916 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|